Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-99
SponsorUniversity of Florida

About this trial

Currently, the standard of care for female patients undergoing radical cystectomy includes the removal of the bladder, pelvic lymph nodes, anterior vagina, uterus, fallopian tubes and ovaries. Removal of female ancillary organs, both in pre and post-menopausal stages is associated with reduction in various quality of life metrics, including sexual health, cognitive decline and depression. Furthermore, removal of ovaries has been associated with increased cardiovascular events, metabolic acidosis, osteoporosis and bone fractures. In premenopausal women, the removal of the ovaries is associated with increased all-cause mortality. From an oncologic standpoint, multi institutional retrospective reviews have demonstrated certain pre-operative radiographic and cystoscopic risk factors that are associated with bladder cancer involvement of female reproductive organs. The absence of these unfavorable risk factors may provide an opportunity to spare women from undergoing unnecessary reproductive organ removal during RC. In doing so, this may eliminate the associated sequelae of removing these additional organs while also providing acceptable oncologic care. The investigators thus propose a decision tool to stratify women undergoing radical cystectomy as favorable and unfavorable for reproductive organ sparing radical cystectomy. This decision tool classification will be used to decide which patients will undergo reproductive organ sparing radical cystectomy versus radical cystectomy in this study.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female ≥ eighteen years of age

Histologically proven diagnosis of urothelial carcinoma of the bladder, including variant histology

Surgical candidate for radical cystectomy

MRI of the pelvis on 1.5T or higher strength magnet.

Disqualifiers

Patients with regional or distant metastatic disease

Non-urothelial bladder cancer.

Not a surgical candidate for radical cystectomy

Unable to have MRI of pelvis that meets the minimum standards in the inclusion criteria above.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Reproductive organ sparing radical cystectomy

    Procedure/Surgery

    Participants on this arm will undergo a reproductive organ sparing radical cystectomy if they are classified as "favorable" based on the decision tool.

  • Radical cystectomy

    Procedure/Surgery

    Participants on this arm will undergo a radical cystectomy if they are classified as "unfavorable" based on the decision tool.

Treatment groups

127 Participants
are divided into 2 treatment groups
Group A: Reproductive organ sparing radical cystectomyExperimental treatment 1 intervention
Group B: Radical cystectomyActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Positive margin rate

Determine the positive margin status rate (based on the surgical pathology report) for the favorable cohort who successfully undergo reproductive organ sparing radical cystectomy

Time frame
120 days

Secondary outcomes

1

Sexual function

Evaluate sexual function as measured by the Female Sexual Function Index (FSFI). The FSFI consists of 19 questions measuring female sexual function across six domains, including desire (2 items), arousal (4 items), lubrication (4 items), orgasm (3 items), satisfaction (3 items), and pain (3 items). Each response is assigned a score of either 0 to 5 or 1 to 5, with a higher score meaning a greater level of sexual functioning. The scores are summed to produce a composite score ranging from 4 to 36, with a higher score meaning better sexual functioning.

Time frame
15 months
2

Quality of life

Evaluate quality of life as measured by the FACT-G questionnaire. The FACT-G measures various aspects of physical, social, emotional, and functional well-being over the past 7 days on a scale of 0-4 (with 0 meaning "Not at all" and 4 meaning "Very much").

Time frame
15 months
3

Local recurrence

Determine the local recurrence rate.

Time frame
12 months
4

Distant recurrence

Determine the distant recurrence rate.

Time frame
12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.